Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
- In the 12 months to Nov 19, 2026, insiders of Cel Sci filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 0 open-market sales (about $0, in 0 filings, by 0 people). One Form 4 can list many transactions.
- In the 12 months before that, they filed 2 open-market purchases (about $220K, in 2 filings) and 0 open-market sales (about $0, in 0 filings).
Contracts, lobbying and filings
- FINRA short interest for CVM on the settlement date of Oct 30, 2026 was 705,801 shares (+6.32% on the previous report), about 5.96 days of average volume.
- For fiscal 2025, the company's proxy statement reported total compensation of $920K for its principal executive officer, and an average of $397K for the other named executive officers.
Company reports, price and press
- Cel Sci filed a Form 8-K on Jun 16, 2026 (Items 1.01, 8.01) that OQRO classes as: signed an important agreement, and reported other company news.
- Cel Sci filed a Form 8-K on May 14, 2026 (Item 1.01) that OQRO classes as: signed an important agreement.
- Cel Sci filed a Form 8-K on May 13, 2026 (Items 1.01, 8.01) that OQRO classes as: signed an important agreement, and reported other company news.
- Press coverage listed by Finnhub: "CEL-SCI’s Dr. Eyal Talor Receives Second International Keynote Invitation on Multikine Head and Neck Cancer Research" (Yahoo, Nov 10, 2026).
- Press coverage listed by Finnhub: "CEL-SCI reports 73.4% five-year survival in Multikine Phase 3 patient analysis" (Yahoo, Oct 29, 2026).
- Press coverage listed by Finnhub: "CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology" (Yahoo, Sep 15, 2026).
- CVM closed at $1.38 on Nov 18, 2026, the last session on or before the end of the period.
- From Oct 19, 2026 to Nov 18, 2026, the close moved from $1.65 to $1.38, a change of −16.4%.